BioCryst Pharmaceuticals Inc

Despite a decisive support failure on elevated volume, extreme oversold conditions have triggered mean-reversion eligibility, flipping the medium-term bias to bullish. However, short-term execution remains unfavorable as price trades below declining 9/20/50 EMAs and rejects on minor rebounds. We will stalk for a pullback into structural support around the 200-day SMA and prior consolidation lows under the Growth at Reasonable Price strategy before considering a long entry.

• ↑Q2 revenue rose 45% YoY to $213.9M, driven by ORLADEYO demand.
• ↑Consensus price target of $20.60 implies 108% upside potential.
• ↓Negative earnings yield and low book-to-price point to premium valuation.